A multi-center phase II study to investigate the safety and activity of SDX-105 (bendamustine) in combination with rituximab in patients with relapsed indolent or mantle cell non-Hodgkin's lymphoma.

Trial Profile

A multi-center phase II study to investigate the safety and activity of SDX-105 (bendamustine) in combination with rituximab in patients with relapsed indolent or mantle cell non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab
  • Indications B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 01 Jun 2010 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2008 Results reported online in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top